Home » AstraZeneca Shuffles, Eliminates Del. R&D Jobs
AstraZeneca Shuffles, Eliminates Del. R&D Jobs
Pharmaceutical company AstraZeneca PLC said Tuesday that it is reorganizing its global research and development operations and eliminating about 1,800 R&D jobs as part of a previously announced cost-cutting plan.
About 550 jobs will be eliminated at AstraZeneca's U.S. headquarters in Delaware as it moves primary research and development elsewhere, the London-based company said.
AstraZeneca also said it will close research sites in the United Kingdom and Sweden, and that about 3,500 R&D jobs will be affected as part of a plan announced in January to cut 8,000 jobs, or 12 percent of its work force, by 2014.
The termination of psychiatric laboratory research in Delaware represents about one-third of the company's R&D work force in the state, where future R&D efforts will focus on shepherding drugs through clinical trials and regulatory approval.
AstraZeneca said its facilities in Boston will see some growth as employees transfer from other sites.
"Given that the company is closing entire facilities around the world, we are thankful that AstraZeneca remains one of our state's largest employers," said Delaware Gov. Jack Markell. "Their commitment to making Delaware their North American center for clinical excellence is a bright spot here. I am encouraged and hopeful that this new focus on making Delaware a clinical hub for their products will put people back to work."
Shares of AstraZeneca rose 44 cents to $44.43 in afternoon trading Tuesday.
AstraZeneca currently has 17 principal R&D sites in eight countries.
While continuing research on cancer and infection drugs and therapies for cardiovascular, gastrointestinal, respiratory, inflammatory and neurological conditions, AstraZeneca said it will cease disease-specific research on drugs to treat thrombosis, acid reflux disease, ovarian and bladder cancers, systemic scleroderma, schizophrenia, bipolar disorder, depression, anxiety, and hepatitis C. It also said it end vaccine research other than for influenza and respiratory syncytial virus.
The changes will result in the closure of the Charnwood research site in Leicestershire, England, and a smaller facility in Cambridge. Employment at Alderley Park, the company's largest R&D site in the U.K., will increase as employees transfer from elsewhere, the company said.
AstraZeneca said it also is looking to sell its London-based Arrow Therapeutics business, and that pharmaceutical development work at its Avlon facility near Bristol will cease, with some roles transferring to other sites in the U.K.
In Sweden, AstraZeneca will close its research site in Lund and boost the work force at its Molndal facility to accommodate activities to be transferred from the Lund and Charnwood sites.
"We have made real strides in improving our efficiency in recent years, but there is a continuing need to adapt our organization in anticipation of future challenges," Executive Vice President of Development Anders Ekblom said in a prepared statement.
"I am also acutely aware that these proposed changes will have a significant impact on our people, and we are committed to providing support to them," he added.
New Asthma Drug Offers Hope for PatientsFrom Forbes
An experimental asthma drug could give new hope to patients for whom existing medicines are not enough
Syrian Pharma Production Nearly Halted by WarFrom AFP
A shortage of foreign currency has brought production to a near halt in Syria
Camfil APC Opens Manufacturing Plant in the UKFrom Camfil
Camfil announced the grand opening of its new 40,000-sq.-ft. facility
Actavis Acquiring Warner Chilcott for $8.5BFrom AP
Actavis to buy Warner Chilcott in an all-stock transaction
Northwest Analytics Launches Next Generation Enterprise Manufacturing Intelligence SolutionFrom Northwest Analytics
NWA Focus EMI Delivers Real Time Process Intelligence and Unique Accelerating Modules - a Shared Knowledge Base and Manufacturing-Centric Collaboration
Innovative Clinical Development Partnership Announced By Quintiles and Merck SeronoFrom MarketWatch.com
Agreement creates unique strategic collaboration for development and clinical trial execution
$15 Billion Myland Offer Rejected By ActavisFrom Bloomberg.com
Actavis has rejected drugmaker Mylan Inc's cash-and-stock offer for $15 billion. They have decided to continue talks to take over Warner Chilcott Plc instead, sources have said.
Rapid Micro Biosystems Offers Workshops at New European Headquarters in MunichFrom Rapid Micro Biosystems
Company hosts hands-on demonstrations of its Growth Direct System
Amgen, Zhejiang Beta Pharma Form Joint VentureFrom FOX Business
Amgen will form a joint venture with Chinese pharma firm to bring its colon cancer drug Vectibix to the Chinese market
Academic Tech Transfer Collaboration Required for Pharma R&D ModelFrom IT News Online
Pharma R&D Model Needs Academic Tech Transfer Collaboration for the Future of Drug Innovation Says New Report
- All news »